IDH1 and central nervous system cancer: IHC results indicated that the positive rate for IDH1 R123H in 125 glioma cases was 49.6% (62/125), while qPCR and first-generation sequencing showed that the mutation rate of the IDH1/2 gene was 46.4% (58/125).